Accelerating Research to
Transform Human Health
Johnson & Johnson Innovation, JLINX is a multifaceted initiative in Europe designed to identify and nurture early-stage companies who are actively pursuing research with the potential to transform human health.
Accelerating early-stage transformative innovation
We catalyze scientific advances by offering start-ups a spectrum of flexible ways to grow and collaborate across the European life science ecosystem.
Located in a fully dedicated facility on the Janssen Campus in Beerse, Belgium, Johnson & Johnson Innovation, JLINX fosters a creative start-up culture, provides access to select scientific talent and resources on the Janssen Campus and through the Johnson & Johnson Innovation network.
JLINX has a focus on human microbiome research, alongside other areas of innovation in pharmaceuticals and cross-disciplinary healthcare solutions.
Johnson & Johnson Innovation, JLINX is a collaboration between Janssen Pharmaceutica NV and bioqube ventures, which will provide an experienced management team to run the day-to-day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying and securing new companies, and supporting the overall scale-up of the new initiative.
Johnson & Johnson Innovation, JLINX will provides entrepreneurs with opportunities to share ideas and collaborate with each other while accessing a unique combination of resources including investment, infrastructure, and access to relevant internal and external scientific, technical and business expertise.
Operating at the Nexus of Science and Business
JLINX complements and extends the Johnson & Johnson Innovation network of initiatives to create a unique environment for scientist entrepreneurs to access capital, infrastructure, resources and expertise needed to build their businesses and advance scientific research and development for the benefit of patients.
JLINX accelerates early-stage transformative innovation, including a focus on the human microbiome as well as broader life-science research.
Investment in promising transformative innovation through Johnson & Johnson Innovation, JLINX is venture-based and the Johnson & Johnson Family of Companies will not hold any specific rights to commercialized products by virtue of the JLINX relationship.
Johnson & Johnson Innovation will works closely with Bioqube Ventures, which will provide an experienced incubator management team to run day-to-day operations, including managing the investment portfolio and relationships with external venture investors, involvement in identifying and securing new companies, and supporting the overall scale-up of the new initiative.
Agility with Scale
Our model combines internal expertise with external entrepreneurial skills creating a start-up culture with selected resources, insights and expertise of a global healthcare leader to accelerate breakthroughs.
Make the Connection
JLINX is open to receive applications. We look forward to discussing opportunities to collaborate with you.
For general inquiries about JLINX, contact:
For investment inquiries, contact:
+32 (0) 14-621-500
Download the Johnson & Johnson
JLINX fact sheet.